Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis

María-Victoria Mateos, MD, PhD, shares the results of a subset analysis of TOURMALINE-MM1, which showed that patients with prior exposure to proteasome inhibitors still benefited from ixazomib treatment.

SHARE